HEALTH

• As of June 18, 2026, a measles outbreak in the U.S. has reached 2,104 confirmed cases across 41 different jurisdictions. • The CDC has issued a warning that increased summer travel may accelerate the spread of the virus, posing a significant risk to families. • This surge highlights a critical public health challenge as officials urge vaccination and awareness to contain the outbreak.

• A study confirming the effectiveness of COVID-19 vaccines was published Tuesday by JAMA Network Open after being blocked by a CDC journal. • The research found the vaccine was approximately 55% effective against hospitalizations and reduced emergency department and urgent care visits by 50%. • The publication gained significant attention because political appointees from the Trump administration previously prevented the findings from appearing in a government health publication.

• The reemergence of Ebola has highlighted the dangerous consequences of the United States withdrawing from global medical research and health initiatives. • This retreat significantly weakens critical infrastructure, including disease surveillance, contact tracing, the staffing of isolation facilities, and the deployment of diagnostic testing. • The lack of US involvement hinders the research and development of new vaccines and treatments, as well as the distribution of essential medical supplies and humanitarian relief.

• The Trump administration announced a multi-pronged initiative on Monday aimed at strengthening the early clinical trial ecosystem within the United States. • As part of this effort, the FDA will reconsider Regenxbio’s gene therapy designed to treat Hunter syndrome, a rare pediatric disease. • This move represents a reversal of previous regulatory rejections, signaling a shift in how the agency evaluates certain high-stakes therapies.

A clinical trial testing two drugs against the Bundibugyo ebolavirus, which is driving a fast-moving outbreak in Central Africa, is set to begin next week, WHO officials said.

• The CDC canceled the publication of a COVID-19 vaccine effectiveness study originally scheduled for its flagship Morbidity and Mortality Weekly Report (MMWR) in April. • CDC leadership blocked the report citing "methodologic weaknesses," though the study has since been released for public review. • Dr. F. Perry Wilson of the Yale School of Medicine highlighted the incident, raising questions about transparency and the potential suppression of data by health officials.

• The National Association of County and City Health Officials (NACCHO), representing over 3,300 local health departments, released new research on public health preparedness and response capacities. • Findings indicate that over half of local health departments feel completely prepared to handle small-scale infectious disease outbreaks (59%), pandemics (57%), and vaccine-preventable diseases (53%). • This data is critical for identifying systemic strengths and gaps in the U.S. public health infrastructure to ensure more effective responses to future health crises.

• The U.S. Department of Health and Human Services (HHS) and the FDA have launched an "unprecedented" initiative to restore American leadership in clinical trials and counter competition from China. • A key component of the plan is an expedited investigational new drug pilot program designed to reduce early trial timelines by as much as 12 months. • Health Secretary Robert F. Califf stated the effort aims to reverse the trend of clinical research moving overseas by making the U.S. the premier location for medicine development.

• The U.S. government has provided doses of an experimental antibody drug developed by Mapp Biopharmaceutical to combat the Ebola outbreak in the Congo. • This decision marks a shift in policy, as the U.S. previously stated the treatment would only be available to high-risk American citizens. • The provision of these doses allows for the drug to be used in clinical trials, accelerating the process of determining its efficacy against the virus.

• The FDA approved the first therapy for primary immunoglobulin A nephropathy in December 2021, marking a significant milestone for patients with this rare kidney disease. • Following this initial approval, several additional novel drugs have received accelerated FDA approval, leading to a rapid expansion of available treatment options. • This "explosion" in therapies is critical as it provides clinicians and patients with a more robust pipeline of medical interventions to manage the disease.

FDA's early-stage clinical trial program, a mysterious single patient gets retatrutide access, and more health news from Morning Rounds

• National data reveals that Assam has accounted for nearly 62% of all Japanese encephalitis (JE) deaths in India since 2018, with outbreaks typically peaking between July and August. • Expert Athira Elssa Johnson emphasizes the urgent need for India to improve controls on food-borne infections, which are being exacerbated by climate change, chemical contaminants, and antimicrobial resistance (AMR). • The report further highlights the growing threat of drug-resistant malaria, which is complicating current medical treatment and disease elimination efforts.

• A study examining COVID-19 vaccine effectiveness was finally published after being blocked from inclusion in a weekly federal government report by the CDC. • The publication follows a separate effort by Robert F. Kennedy Jr., who petitioned the FDA to revoke the authorization of all COVID-19 vaccines. • The FDA denied Kennedy's petition three months later, maintaining that vaccines are safe and effective based on clinical trials involving tens of thousands of participants.

• The American Journal of Health-System Pharmacy has outlined the pharmaceutical pipeline for novel drug approvals anticipated between 1Q 2026 and 4Q 2026. • The upcoming pipeline focuses on therapies for rare inherited genetic disorders, immunologic and inflammatory diseases, and advancements in gene therapy and targeted oncology. • This tracking is critical for health-system pharmacists to effectively manage hospital formularies, allocate financial resources, and optimize patient care.

• The Centers for Medicare & Medicaid Services (CMS) has proposed a new rule to establish a permanent framework for its Medicare drug price negotiation program. • Scheduled to begin in 2029, the program focuses on negotiating and renegotiating prices for expensive, single-source drugs to reduce costs for millions of patients. • This move is significant as it aims to provide drug manufacturers with greater long-term certainty while increasing the affordability of critical medications.

• First10EM's June 2026 research roundup provides a critical appraisal of a recent emergency medicine trial regarding the use of whole blood. • The study yielded statistically negative results, but the data revealed a 5% increase in mortality among patients treated with whole blood. • These findings are significant because whole blood remains an unproven therapy, suggesting that its clinical use may currently be harmful.

• The U.S. Department of Justice announced the 2026 National Health Care Fraud Takedown, charging 455 defendants for their roles in massive fraud and opioid abuse schemes. • The group of defendants includes 90 doctors and other licensed medical professionals who allegedly submitted over $6.5 billion in false health care claims. • This enforcement action is critical as the schemes caused significant patient harm, including deaths, highlighting the lethal consequences of medical fraud.

• MarketBeat’s stock screener tool identified Eli Lilly and Company, Pfizer, and Abbott Laboratories as the top pharmaceutical stocks to watch on June 24th. • These companies are highlighted for their roles in the research, development, manufacturing, and sale of medicines and healthcare products. • This selection serves as a guide for investors looking to monitor high-potential assets within the pharmaceutical sector.